Germany promotes G20 initiative against antimicrobial resistance
The German government's Federal Ministry of Education and Research (BMBF) is dedicating up to EUR 500 million in the coming decade to support the G20's international research initiative devoted to fighting antimicrobial resistance (AMR). The initiative was announced in the G20 leaders' final declaration at the end of the G20 summit in July. The BMBF's funding pledge came shortly afterwards.
Germany has played a decisive role in getting the AMR initiative up and running during its G20 presidency. Ahead of the summit in Hamburg, the country organized and held the first-ever meeting solely for G20 health ministers. AMR topped that meeting's agenda. During the talks held in Berlin in May, the G20 health ministers called specifically for greater support for the Joint Programming Initiative on AMR (JPI AMR) and the Global Antibiotic Research & Development Partnership (GARDP).
One of the initiative's key, new objectives is to set up a joint platform that brings together all significant R&D partners in the G20 in order to strengthen and better coordinate research in this area. The AMR initiative will begin its work in the autumn. It is open to any country and organization, including private supporters.
An example for international cooperation within the platform, says the BMBF, is the Coalition for Epidemic Preparedness and Innovations (CEPI). Germany is also taking part in this program, in which countries, foundations, civil society and affected countries engage in cooperative research to develop vaccines against diseases that could cause global epidemics.